Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Ex-Novartis Employee Nabbed over Diovan Data Tampering: Reports
June 11, 2014
-
REGULATORY Govt Tilting Toward Etching Annual NHI Price Revision in Fiscal Blueprint
June 10, 2014
-
ORGANIZATION Generic Versions of Combination Drug Exforge to Be Named “Amvalo”: JSGM
June 10, 2014
-
REGULATORY Researchers Aiming to Craft Guide for Ultra-Orphan Drug Development
June 9, 2014
-
REGULATORY MHLW, Pharma Officials Take to Nagata-cho in Crusade against Yearly NHI Price Revision
June 6, 2014
-
BUSINESS AbbVie Can Achieve 100 Billion Yen Sales Target Ahead of Schedule: President
June 6, 2014
-
REGULATORY MHLW Gets Ball Rolling on OTC Diagnostics Deregulation
June 5, 2014
-
BUSINESS Astellas to Issue Monthly EPPV Reports on Suglat for One Year: Product Manager
June 5, 2014
-
REGULATORY MHLW Should Clear Hurdles, Revise NHI Prices Annually: MOF Budget Examiner
June 4, 2014
-
BUSINESS Teijin Ups FY2015 Japan Sales Target for Feburic to 20-Plus Billion Yen
June 3, 2014
-
REGULATORY Fiscal System Council Renews Call for Annual NHI Price Revision, MHLW Still Guarded
June 2, 2014
-
BUSINESS Daiichi Sankyo to Tout Quick Cardiac Event Reduction for Efient
May 30, 2014
-
REGULATORY Chuikyo to Assess Cost-Effectiveness of 5 Listed Drugs, Industry Leery of Price Cuts
May 29, 2014
-
BUSINESS Novartis to Divest Flu Vaccine Biz within 18 Months
May 28, 2014
-
BUSINESS Taisho Toyama to Center on Safety for Lusefi Promotion: Product Manager
May 27, 2014
-
BUSINESS 3 More SGLT-2 Inhibitors Make Japan Debuts to Trail Suglat
May 26, 2014
-
BUSINESS Blopress AG Rollout Won’t Coincide with June Listing: ASKA Pres.
May 23, 2014
-
BUSINESS Teva Pharma Japan to Postpone NHI Price Listing of All Generics Including Valsartan in June
May 23, 2014
-
ORGANIZATION Dainippon Pres. Tada Elected New Chief of JPMA
May 22, 2014
-
BUSINESS AZ to Highlight Global Data to Push Forxiga: Primary Care Head
May 21, 2014
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…